Seahorse signs agreement with Primetech

Seahorse extracellular flux (XF) analyzers provide method to non-invasively measure the two major energy producing pathways – mitochondrial respiration and glycolysis – in living cells. The microplate-based technology is said to allow scientists to assess the impact of drugs, genetic modifications and environment by monitoring the rate that cells consume oxygen and produce metabolic byproducts including acid and carbon dioxide.

Ryosuke Ogihara, CEO of Primetech, said: “Our customers are interested in studying mitochondrial dysfunction, and in particular its role in cancer, obesity and age-related diseases. Seahorse XF instruments offer the only practical way to study mitochondria in whole cells.”